Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

De Novo Cleared For Sonablate Device After Panel Rejects PMA

This article was originally published in The Gray Sheet

Executive Summary

The ultrasound unit for the ablation of prostate tissue was cleared via the de novo process. Last year, an FDA advisory panel recommended against approving a PMA on the device due to what the experts said were insufficient clinical trial results.

Advertisement

Related Content

FDA Panel Rejects Sonablate 450 HIFU Device For Prostate Cancer

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

MT034298

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel